SCHEMBL23748282

SCHEMBL23748282

C=C(C)CNC(=O)c1[nH]ccc(=O)c1OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
KMT2A Q03164 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 2/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
FKBP1A P62942 1/20 0.40
GAA P10253 3/20 0.39
LMNA P02545 2/20 0.39
HPGD P15428 2/20 0.38
NSD2 O96028 1/20 0.38
ABL1 P00519 1/20 0.38
PPARG P37231 1/20 0.38
RIN1 Q13671 1/20 0.38
NCOR2 Q9Y618 1/20 0.38
BRD4 O60885 1/20 0.38
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10188493 0.83 POLB (0.60) POLBKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL23748321 0.83 POLB (0.51) POLBKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL19588885 0.81 POLB (0.58) POLBL3MBTL1ALDH1A1USP2TSHR
SCHEMBL23748281 0.81 POLB (0.49) POLBKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL24353633 0.81 POLB (0.46) POLBKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL24354319 0.80 POLB (0.46) POLBKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL21259220 0.79 POLB (0.62) POLBKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL23748352 0.79 POLB (0.47) POLBKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL10188488 0.79 POLB (0.64) POLBKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL10188507 0.78 POLB (0.52) POLBKMT2AL3MBTL1MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 POLB 74/4885KMT2A 1447/4885L3MBTL1 2124/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP POLB 32/4885KMT2A 1718/4885L3MBTL1 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.